Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua B. Cohen Sells 4,135 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Free Report) CEO Joshua B. Cohen sold 4,135 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total transaction of $77,448.55. Following the completion of the sale, the chief executive officer now owns 3,023,002 shares of the company’s stock, valued at approximately $56,620,827.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amylyx Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ AMLX opened at $3.24 on Friday. Amylyx Pharmaceuticals, Inc. has a twelve month low of $2.70 and a twelve month high of $33.33. The company has a market capitalization of $219.61 million, a price-to-earnings ratio of 4.63, a PEG ratio of 0.12 and a beta of -0.66. The firm has a 50-day moving average of $14.79 and a two-hundred day moving average of $15.86.

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. The company had revenue of $108.45 million during the quarter, compared to the consensus estimate of $106.40 million. During the same period in the prior year, the company earned ($0.65) EPS. As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its stake in Amylyx Pharmaceuticals by 5,980,997.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,751,305 shares of the company’s stock valued at $40,499,000 after buying an additional 2,751,259 shares in the last quarter. Vanguard Group Inc. lifted its stake in Amylyx Pharmaceuticals by 253.6% during the third quarter. Vanguard Group Inc. now owns 3,514,356 shares of the company’s stock valued at $98,929,000 after buying an additional 2,520,355 shares in the last quarter. BlackRock Inc. lifted its stake in Amylyx Pharmaceuticals by 223.6% during the third quarter. BlackRock Inc. now owns 2,295,834 shares of the company’s stock valued at $64,628,000 after buying an additional 1,586,402 shares in the last quarter. Stonepine Capital Management LLC lifted its stake in Amylyx Pharmaceuticals by 124.4% during the third quarter. Stonepine Capital Management LLC now owns 2,515,868 shares of the company’s stock valued at $46,066,000 after buying an additional 1,394,840 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Amylyx Pharmaceuticals by 121.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock valued at $31,131,000 after buying an additional 932,000 shares in the last quarter. 87.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Evercore ISI reiterated an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Deutsche Bank Aktiengesellschaft began coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $36.00 price target for the company. Robert W. Baird lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. SVB Leerink downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. Finally, Mizuho reduced their price objective on shares of Amylyx Pharmaceuticals from $46.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, December 21st. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $38.33.

View Our Latest Report on Amylyx Pharmaceuticals

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

Featured Stories

Insider Buying and Selling by Quarter for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.